Event > Conference >
We are delighted to be attending ICT’s 16th Annual Congress of Toxicology. The conference looks to unite the world’s best toxicological scientists in the historical city of Maastricht, the Netherlands.
Head to our exhibition stand – #59
We look forward to meeting you to discuss how to improve the predictability of human toxicity using organ-on a chip. Reveal the mechanisms of drug-induced liver injury (DILI) with PhysioMimix® OOC single-and multi organ microphysiological systems.
You can also catch us at two events
Lunch Industry Symposium –
CN Bio & AstraZeneca
Tues, September 20th @ 12:00 – 13:00 – Room 23B
Addressing the challenges of generating translational pre-clinical liver toxicology data – a direct discussion between pharma and an Organ-on-a-chip solution provider. Dr. Tomasz Kostrzewski, VP Science & Technology CN Bio & Sebastian Prill, Associate Director, Hepatic Safety AstraZeneca.
Entitled: “Evaluating different modalities of drug-induced liver injury using a sensitive and selective human liver microphysiological system and clinical biomarkers,” our E-Poster can be downloaded throughout the event. 1st author Dr Ovidiu Novac will attend the event and will be on hand to answer any questyions. If you want to arrange a meeting during the event, don’t hesitate to contact us.
Industry symposium with AstraZeneca
Addressing the challenges of generating translational pre-clinical liver toxicology data – a direct discussion between pharma and Organ-on-a-chip solution provider
Microphysiological systems (MPS) are cutting-edge cell culture technologies that emulate the physiological microenvironment and functionality of human organs. Here we discuss how to rapidly and reliably integrate liver MPS into drug discovery and development workflows to gain translational pre-clinical data. Lunch Provided
Dr Sebastian Prill – Associate Director, Hepatic Safety at AstraZeneca
Associate Director, Hepatic Safety – Clinical Pharmacology and Safety Sciences at AstraZeneca, Sebastian Prill is a cell biologist and tissue engineer by training and received his PhD from Potsdam University, Germany. He has a strong research interest in complex cellular in vitro models, with expert knowledge in liver-on-chip systems, disease modelling, metabolic real-time monitoring on-chip, as well as oligonucleotide safety. He is enthusiastic about cutting-edge and innovative cell culture technologies, merging biology and engineering for the generation of meaningful data facilitating preclinical-to-clinical translation.
Date: Tuesday September 20, 2022
Time: 12:00 -13:00
Hosted by: CN Bio and Astra Zeneca
Presentation from: Dr Tomasz Kostrzewski, CN Bio & Sebastian Prill, Associate Director, Hepatic Safety, AstraZeneca.
Chairperson: Dr Adrian Rea, CN Bio
Our poster presentation
Evaluating different modalities of drug-induced liver injury using a sensitive and selective human liver microphysiological system and clinical biomarkers
Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the USA and Europe and a determining factor for drug attrition during the development process with over 1000 FDA-approved drugs currently known to potentially cause different levels of DILI severity in humans. Over recent years focus has turned to human in vitro 3D liver models to provide solutions to standard in vitro cell culture models’ limitations in detecting chronic drug exposure. Here we describe a human liver microphysiological system (MPS) comprised of human primary liver parenchymal and non-parenchymal cells cultured in 3D microtissues on an engineered scaffold under perfusion.
Location: Electronic Poster
Authors: Ovidiu Novac, Raul Silva, David Hughes, Tomasz Kostrzewski
Our Team at ICT
Dr Tomasz Kostrzewski is VP – Science and Technology at CN Bio with more than 15 years of experience in molecular and cellular biology research. Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation. At Imperial College London he completed both an MRes and PhD in the department of Cell and Molecular Biology. He has significant experience in advanced (3D) mammalian cell culture, gene expression analysis and immune cell function. Additionally, he has previous experience of working in biopharmaceutical drug discovery and development with GlaxoSmithKline. In 2017, he was promoted to head of biology at CN Bio and is responsible for biological model development and collaborative research projects and in 2022 he took responsibility for all technical activities including developing new products, technologies and assays. TK has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. TK has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Dr Ovidiu Novac is a Senior Scientist at CN Bio and a knowledgeable organ-on-a-chip (OOC) expert. Ovi performed as a lead biological scientist in the NASH-in-a-Box project, is a knowledgeable organ-on-a-chip (OOC) expert, and has experience in assessing drug-induced liver injury in vitro. Ovi has a background in the developmental stage of pharmaceutical and dermatological formulations and their performance assessment on human skin tissue ex vivo (topical and transdermal), and for strategic planning for further evaluation. During his time spent in the pharma industry, he contributed to delivering high-quality results used for marketing purposes and in regulatory submissions. Ovi holds a BSc in biomaterials and prosthetic technologies and a PhD in chemistry and has been involved in research on controlled drug delivery systems since 2006.
Dr Atefeh Mobasseri, Field Application Scientist at CN Bio, has an extensive background in tissue engineering and regenerative medicine. Before joining CN Bio, she gained a PhD in Biomedical materials from the University of Manchester and carried out postdoctoral roles at the University of Manchester and Kings College London investigating the interaction, and effect, of 3D scaffolds on cellular behaviour. Since joining CN Bio, she has been supporting their European customers in using CN Bio’s range of PhysioMimixTM systems to generate high content, human-relevant, data.
A seasoned business developer with extensive commercial experience in the life science sector, Adrian Rea joined CN-Bio Innovations as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.